Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

286 articles with Tenax Therapeutics (Formerly Known As Oxygen Biotherapeutics, Inc.)

• Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  3/22/2023

  Tenax Therapeutics, Inc. announced today that the Company has been issued a patent by the United States Patent and Trademark Office (USPTO) with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension associated with HFpEF.

• Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

  2/3/2023

  Tenax Therapeutics, Inc. announced today the pricing of a public offering of (i) 8,666,666 shares of its common stock (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to 17,333,332 shares of its common stock.

• Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

  2/1/2023

  Tenax Therapeutics, Inc. (Nasdaq: TENX) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application with claims covering the use of IV levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).

• Tenax Therapeutics Announces Reverse Stock Split - Jan 04, 2023

  1/4/2023

  Tenax Therapeutics, Inc. announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20.

• 

  Clinical Catch-Up: SIFI, BeiGene and Novo Report New Data (Updated)

  10/13/2022

  SIFI, BeiGene and Novo Holdings shared promising updates on their proposed treatments for acanthamoeba keratitis, relapsed or refractory CCL and myasthenia gravis.

• Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  10/10/2022

  Tenax Therapeutics, Inc. announces the presentation of positive data from a study of PH-HFpEF patients being treated with oral levosimendan.

• Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

  9/15/2022

  Tenax Therapeutics, Inc. today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value.

• Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

  5/25/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201.

• Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

  5/23/2022

  Tenax Therapeutics, Inc. today announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial hypertension (“PAH”).

• Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

  5/18/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 10,596,027 Units at a purchase price of $0.755.

• Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

  3/31/2022

  Tenax Therapeutics, Inc. today reported financial results for the year ended December 31, 2021 and provided a business update.

• Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

  3/30/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), today announced that two presentations will be made at the upcoming American College of Cardiology (ACC) Scientific Sessions featuring the Company’s lead drug candidates, imatinib and levosimendan.

• 

  BioSpace Movers & Shakers, Feb. 4

  2/4/2022

  Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

• Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

  1/31/2022

  Tenax Therapeutics, Inc. announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022.

• Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

  1/12/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company’s subcutaneous formulation of levosimendan.

• Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

  1/4/2022

  Tenax Therapeutics, Inc. (Nasdaq: TENX), today provided patent and clinical program updates for its two lead product candidates, TNX-103 for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF), and TNX-201 for the treatment of pulmonary arterial hypertension (PAH).

• Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

  11/16/2021

  Tenax Therapeutics, Inc. today reported financial results for the third quarter of 2021 and provided a business update.

• Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)

  10/6/2021

  Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for a novel formulation of imatinib.

• Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

  9/28/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview at the virtual Benziga Healthcare Small Cap Conference being held from September 29-30, 2021.

• Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference.